A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies
Pierre‐André Gilormini, V. Narasimharao Thota, Anthony Fers-Lidou, Roger A. Ashmus, Matthew B. Nodwell, Jacob Brockerman, Chu‐Wei Kuo, Yang Wang, Taylor E. Gray, Nitin Nitin, Anthony W. McDonagh, Shih-Yun Guu, Nurşah Ertunç, Dominick Y. Yeo, Wesley F. Zandberg, Kay‐Hooi Khoo, Robert Britton, David J. Vocadlo
Abstract
The fucosylation of glycoproteins regulates diverse physiological processes. Inhibitors that can control cellular levels of protein fucosylation have consequently emerged as being of high interest. One area where inhibitors of fucosylation have gained significant attention is in the production of afucosylated antibodies, which exhibit superior antibody-dependent cell cytotoxicity as compared to their fucosylated counterparts. Here, we describe β-carbafucose, a fucose derivative in which the endocyclic ring oxygen is replaced by a methylene group, and show that it acts as a potent metabolic inhibitor within cells to antagonize protein fucosylation. β-carbafucose is assimilated by the fucose salvage pathway to form GDP-carbafucose which, due to its being unable to form the oxocarbenium ion-like transition states used by fucosyltransferases, is an incompetent substrate for these enzymes. β-carbafucose treatment of a CHO cell line used for high-level production of the therapeutic antibody Herceptin leads to dose-dependent reductions in core fucosylation without affecting cell growth or antibody production. Mass spectrometry analyses of the intact antibody and N -glycans show that β-carbafucose is not incorporated into the antibody N -glycans at detectable levels. We expect that β-carbafucose will serve as a useful research tool for the community and may find immediate application for the rapid production of afucosylated antibodies for therapeutic purposes.